New approaches in metastatic melanoma: biological and molecular targeted therapies

References

• Bajetta E, Del Vecchio M, Bernard-Marty C et al. Metastatic melanoma: chemotherapy. Semin. Oncol.29, 427–445 (2002).
   PubMed Web of Science ®Google Scholar
• Buzaid AC. Strategies for combining chemotherapy and biotherapy in melanoma. Cancer Control7, 185–197 (2000).
   PubMedGoogle Scholar
• Becker JC, Kampgen E, Brocker E. Classical chemotherapy for metastatic melanoma. Clin. Exp. Dermatol.25, 503–508 (2000).
   PubMed Web of Science ®Google Scholar
• Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin. Oncol.29, 413–426 (2002).
   PubMedGoogle Scholar
• Mandara M, Nortilli R, Sava T, Cetto GL. Chemotherapy for metastatic melanoma. Expert Rev. Anticancer Ther.6, 121–130 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.Angiogenesis7, 335–345 (2004).
   PubMedGoogle Scholar
• Rini BI. Sorafenib. Expert Opin. Pharmacother.7, 453–461 (2006).
   PubMed Web of Science ®Google Scholar
• Rudin M, McSheehy PM, Allegrini PR et al. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.NMR Biomed.18, 308–321 (2005).
   PubMedGoogle Scholar
• Gartside MG, Curtis A, Yudt L et al. Identification of FGFR2 as a novel melanoma oncogene. Am. Assoc. Cancer Res. Meeting Abstracts 608–c–609 April 16–20th (2005).
   Google Scholar
• Halaban R, Rubin JS, Funasaka Y et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene7, 2195–2206 (1992).
   PubMedGoogle Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24, 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res.15, 283–285 (2005).
   PubMedGoogle Scholar
• Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res.8, 3468–3474 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev.24, 273–285 (2005).
   PubMed Web of Science ®Google Scholar
• Meier F, Schittek B, Busch S et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci.10, 2986–3001 (2005).
   PubMed Web of Science ®Google Scholar
• Flaherty K. Targeting the MAPK in cancer. Presented at: Am. Assoc. Cancer Res. Washington, DC, USA, April 1–5th (2006).
   Google Scholar
• Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res.16, 97–103 (2006).
   PubMedGoogle Scholar
• Rimoldi D, Salvi S, Lienard D et al. Lack of BRAF mutations in uveal melanoma. Cancer Res.63, 5712–5715 (2003).
   PubMed Web of Science ®Google Scholar
• Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst.95, 1878–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95, 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty K. Phase II trials of BAY 43-9006 alone or in combination with chemotherapy in metastatic melanoma. Presented at: 6th World Melanoma Conference. Vancouver, Canada, September 6–10th (2005).
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan B, Utting JF, Higginson A, Thomas AL, Steward WP, Horsfield MA. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br. J. Cancer94, 1420–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Lorigan P, Lorrie P, Chao D et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J. Clin. Oncol.24 (2006) (Abstract 8012).
   Google Scholar
• Amaravadi RK, Schuchter LM, Kramer A et al. Preliminary results of a randomized Phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J. Clin. Oncol.24 (2006) (Abstract 8009).
   Google Scholar
• Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res.12, S2366–S2370 (2006).
   PubMedGoogle Scholar
• Hoek KS, Schlegel NC, Brafford P et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res.19, 290–302 (2006).
   PubMedGoogle Scholar
• Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol.23, 5281–5293 (2005).
   PubMed Web of Science ®Google Scholar
• Haas N, Smalley K, Contractor R, Sproesser K, Herlyn M. The novel MEK inhibitor AZD6244/ARRY142886 inhibits the growth of melanomas harboring the BRAFV600E mutation in vitro and in vivo.Melanoma Res.16, S92–S93 (2006).
   Google Scholar
• Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol.21, 4342–4349 (2003).
   PubMed Web of Science ®Google Scholar
• Ivan D, Niveiro M, Diwan AH et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with imatinib mesylate (STI571, Gleevec). J. Cutan. Pathol.33, 280–285 (2006).
   PubMedGoogle Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92, 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106, 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR et al. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res.65, 7462–7469 (2005).
   PubMed Web of Science ®Google Scholar
• Yang L, Dan HC, Sun M et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res.64, 4394–4399 (2004).
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer104, 1045–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Lasithiotakis K, Schittek B, Sinnberg T et al. Combined targeting of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment. Melanoma Res.16, S94–S95 (2006).
   Google Scholar
• Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J. Clin. Oncol.24, 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Martus P, Punt CJ et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin. Eur. J. Cancer38, 1501–1511 (2002).
   PubMed Web of Science ®Google Scholar
• Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol.24, 267–296 (2004).
   PubMed Web of Science ®Google Scholar
• Yang J, Price MA, Neudauer CL et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J. Cell Biol.165, 881–891 (2004).
   PubMed Web of Science ®Google Scholar
• McCarthy J, Price MA, Yang J, Lida J, Turley E, Ferrone S. Melanoma chondroitin sulfate proteoglycan promotes anchorage-independent growth of melanoma cells through activation of ERK1/2. Melanoma Res.16, S95, ABS-0174 (2006).
   Google Scholar
• Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2–23 by fusion with interleukin 2. Cancer Res.65, 6976–6983 (2005).
   PubMed Web of Science ®Google Scholar
• Hersey P, Sosman J, O’Day SM et al. A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human αvβ3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J. Clin. Oncol.23 (2005) (Abstract 7507).
   Google Scholar
• Keilholz U. Biochemotherapy of melanoma. Forum (Genova)13, 158–165; quiz 189 (2003).
   PubMedGoogle Scholar
• Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-a-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol.23, 6747–6755 (2005).
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr. Opin. Investig. Drugs6, 1234–1239 (2005).
   PubMedGoogle Scholar
• Weinreich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to α-interferon or low-dose interleukin-2. J. Immunother.25, 185–187 (2002).
   PubMed Web of Science ®Google Scholar
• Pilla L, Valenti R, Marrari A et al. Vaccination: role in metastatic melanoma. Expert Rev. Anticancer Ther.6, 1305–1318 (2006).
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol.20, 4181–4190 (2002).
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol.20, 4549–4554 (2002).
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol.24, 175–208 (2006).
   PubMed Web of Science ®Google Scholar
• Romero P, Valmori D, Pittet MJ et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev.188, 81–96 (2002).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115, 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol.175, 6169–6176 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10, 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Appay V, Jandus C, Voelter V et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol.177, 1670–1678 (2006).
   PubMed Web of Science ®Google Scholar
• Zippelius A, Batard P, Rubio-Godoy V et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res.64, 2865–2873 (2004).
   PubMed Web of Science ®Google Scholar
• Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and Phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother.53, 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Pittet MJ, Rimoldi D et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol.13, 461–472 (2003).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Pittet MJ, Guillaume P et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J. Immunother.27, 298–308 (2004).
   PubMedGoogle Scholar
• Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S. Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J. Immunol. Methods309, 192–199 (2006).
   PubMedGoogle Scholar
• Speiser DE, Baumgaertner P, Barbey C et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol.177, 1338–1348 (2006).
   PubMed Web of Science ®Google Scholar
• Faries MB, Czerniecki BJ. Dendritic cells in melanoma immunotherapy. Curr. Treat. Options Oncol.6, 175–184 (2005).
   PubMedGoogle Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo.Immunobiology211, 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Bharti A, Khaleque AA et al. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J. Immunol.177, 5946–5955 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14639–14645 (2004).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol.23, 2346–2357 (2005).
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol.6, 383–393 (2006).
   PubMed Web of Science ®Google Scholar
• Michielin O, Blanchet JS, Fagerberg T et al. Tinkering with nature: the tale of optimizing peptide based cancer vaccines. Cancer Treat. Res.123, 267–291 (2005).
   PubMedGoogle Scholar
• Le Gal FA, Ayyoub M, Dutoit V et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother.28, 252–257 (2005).
   PubMed Web of Science ®Google Scholar
• Liu H, Leung BP. CD4+CD25+ regulatory T cells in health and disease. Clin. Exp. Pharmacol. Physiol.33, 519–524 (2006).
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med.174, 561–569 (1991).
   PubMed Web of Science ®Google Scholar
• Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res.16, 379–383 (2006).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.190, 355–366 (1999).
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother.28, 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer106, 2437–2444 (2006).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23, 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P et al. Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol.23, 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100, 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23, 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• McMillin DW, Hewes B, Gangadharan B, Archer DR, Mittler RS, Spencer HT. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum. Gene Ther.17, 798–806 (2006).
   PubMedGoogle Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307, 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med.4, 408–414 (1998).
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Kroon BB, Di Filippo F et al. Isolated limb perfusion: the European experience. Surg. Oncol. Clin. North Am.10, 821–832, ix (2001).
   PubMedGoogle Scholar
• Cornett WR, McCall LM, Petersen RP et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J. Clin. Oncol.24, 4196–4201 (2006).
   PubMed Web of Science ®Google Scholar
• Lejeune F, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. (Letter to the Editor). J. Clin. Oncol.25(11), 1449–1450 (2007).
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun.6, 6 (2006).
   PubMedGoogle Scholar
• Borsi L, Balza E, Carnemolla B et al. Selective targeted delivery of TNFα to tumor blood vessels. Blood102, 4384–4392 (2003).
   PubMed Web of Science ®Google Scholar
• Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin. Cancer Res.12, 175–182 (2006).
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang W, Cheung L, Wu Q, Li C, Rosenblum M. The anti-gp240 fusion toxin scFvMEL/TNF shows potent antitumor activity and synergy with chemotherapeutic agents. Proc. Am. Assoc. Cancer Res. (2005) (Abstract 687).
   Google Scholar
• Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10, 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Danielsen T, Rofstad EK. The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts. Br. J. Cancer82, 1528–1534 (2000).
   PubMedGoogle Scholar
• Lejeune F. Improving drug penetration in tumors by targeting tumor vascularization. Targ. Oncol.1(2), 90–96 (2006).
   Google Scholar
• Brunstein F, Santos ID, Ferreira LM, van Tiel ST, Eggermont AM, Ten Hagen TL. Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats. Acta Cir. Bras.20, 275–279 (2005).
   PubMedGoogle Scholar
• Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer82, 812–817 (2000).
   PubMed Web of Science ®Google Scholar
• Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer107, 1883–1890 (2006).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol.21, 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Laber DA, Okeke RI, Arce-Lara CM et al. A Phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J. Cancer Res. Clin. Oncol.132, 611–616 (2006).
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc. Res.69, 56–63 (2005).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer90, 955–961 (2004).
   PubMed Web of Science ®Google Scholar
• Zaman K, Driscoll R, Hahn D et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int. J. Cancer118, 755–764 (2006).
   PubMed Web of Science ®Google Scholar
• Schadendorf D. Gene-based therapy of malignant melanoma. Semin. Oncol.29, 503–512 (2002).
   PubMedGoogle Scholar
• Yeung ML, Bennasser Y, Le SY, Jeang KT. siRNA, miRNA and HIV: promises and challenges. Cell Res.15, 935–946 (2005).
   PubMed Web of Science ®Google Scholar
• Katagiri Y, Hozumi Y, Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo.J. Dermatol. Sci.42, 215–224 (2006).
   PubMedGoogle Scholar
• Zhang L, Huang J, Yang N et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA103, 9136–9141 (2006).
   PubMed Web of Science ®Google Scholar
• Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Res.66, 1883–1890; comment and discussion 1891–1886 (2006).
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res.65, 9328–9337 (2005).
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res.65, 4320–4333 (2005).
   PubMed Web of Science ®Google Scholar
• Locati M, Otero K, Schioppa T et al. The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy57, 972–982 (2002).
   PubMed Web of Science ®Google Scholar
• Scala S, Giuliano P, Ascierto PA et al. Human melanoma metastases express functional CXCR4. Clin. Cancer Res.12, 2427–2433 (2006).
   PubMed Web of Science ®Google Scholar
• Kim J, Mori T, Chen SL et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann. Surg.244, 113–120 (2006).
   PubMed Web of Science ®Google Scholar
• Chen X, Beutler JA, McCloud TG et al. Tannic acid is an inhibitor of CXCL12 (SDF-1α)/CXCR4 with antiangiogenic activity. Clin. Cancer Res.9, 3115–3123 (2003).
   PubMedGoogle Scholar
• Hatse S, Princen K, De Clercq E et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol.70, 752–761 (2005).
   PubMed Web of Science ®Google Scholar
• Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med.12, 406–414 (2006).
   PubMed Web of Science ®Google Scholar
• Garraway LA, Widlund HR, Rubin MA et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature436, 117–122 (2005).
   PubMed Web of Science ®Google Scholar
• McGill GG, Horstmann M, Widlund HR et al. E. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell109, 707–718 (2002).
   PubMed Web of Science ®Google Scholar
• Du J, Widlund HR, Horstmann MA et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell6, 565–576 (2004).
   PubMed Web of Science ®Google Scholar
• McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem.281, 10365–10373 (2006).
   PubMed Web of Science ®Google Scholar
• Larue L, Delmas V. The WNT/β-catenin pathway in melanoma. Front. Biosci.11, 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Massi D, Tarantini F, Franchi A et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod. Pathol.19, 246–254 (2006).
   PubMedGoogle Scholar
• Nickoloff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Qin JZ. Notch and NOXA-related pathways in melanoma cells. J. Investig. Dermatol. Symp. Proc.10, 95–104 (2005).
   PubMedGoogle Scholar
• Weeraratna AT, Jiang Y, Hostetter G et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell1, 279–288 (2002).
   PubMed Web of Science ®Google Scholar
• Hipfel R, Schittek B, Bodingbauer Y, Garbe C. Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. Br. J. Cancer82, 1149–1157 (2000).
   PubMedGoogle Scholar
• Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. Upregulated expression of the Y-box binding protein (YB-1) in melanoma cells enforces melanoma proliferation, survival and invasion and increases chemoresistance. Melanoma Res.16, S104 (2006).
   Google Scholar